Presence of a pleural effusion. 36. McCarten KM, Metzger ML, Drachtman RA, et al.: Significance of pleural effusion at prognosis in pediatric Hodgkin lymphoma: a report from Children’s Oncology Group protocol AHOD0031. 33. Marks LJ, McCarten KM, Pei Q, et al.: Pericardial effusion in Hodgkin lymphoma: a report from the Children’s Oncology Group AHOD0031 protocol. Factors related with adverse result, quite a few of which are collinear, ended up evaluated by multivariable examination in the Children’s Oncology Group (COG) AHOD0031 (NCT00025259) trial for https://streempornfree.com/Tag/chaterbate-mobile 1,734 kids with intermediate-danger Hodgkin lymphoma. 39. Friedman DL, Chen L, Wolden S, et al.: Dose-intense reaction-based chemotherapy and radiation treatment for little ones and adolescents with newly identified intermediate-hazard hodgkin lymphoma: a report from the Children’s Oncology Group Study AHOD0031. 35. Schwartz CL, Chen L, McCarten K, et al.: Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event-totally free survival in Hodgkin Lymphoma: A Report from the Children’s Oncology Group. 37. Keller FG, Castellino SM, Chen L, et al.: Results of the AHOD0431 trial of response adapted remedy and a salvage strategy for restricted phase, classical Hodgkin lymphoma: A report from the Children’s Oncology Group. 34. Smith RS, Chen Q, Hudson MM, et al.: Prognostic variables for little ones with Hodgkin’s illness addressed with mixed-modality therapy.
7. Rudant J, Orsi L, Monnereau A, et al.: Childhood Hodgkin’s lymphoma, non-Hodgkin’s lymphoma and aspects associated to the immune method: the Escale Study (SFCE). 25. Biggar RJ, Jaffe ES, Goedert JJ, et al.: Hodgkin lymphoma and immunodeficiency in people with HIV/AIDS. 24. Straus SE, Jaffe ES, Puck JM, et al.: The advancement of lymphomas in people with autoimmune lymphoproliferative syndrome with germline Fas mutations and faulty lymphocyte apoptosis. 2019 08 15 381(7):603-613. Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ, Type 1 Diabetes TrialNet Study Group. 12. Mack TM, Cozen W, Shibata DK, et al.: Concordance for Hodgkin’s ailment in equivalent twins suggesting genetic susceptibility to the younger-grownup type of the sickness. sixteen. Claviez A, Tiemann M, Lüders H, et al.: Impact of latent Epstein-Barr virus an infection on end result in young children and adolescents with Hodgkin’s lymphoma. As the remedy of Hodgkin lymphoma improved, aspects involved with final result became a lot more difficult to discover.
21. Kanakry JA, Li H, Gellert LL, et al.: Plasma Epstein-Barr virus DNA predicts result in state-of-the-art Hodgkin lymphoma: correlative assessment from a massive North American cooperative group trial. 15. Welch JJG, Schwartz CL, Higman M, et al.: Epstein-Barr virus DNA in serum as an early prognostic marker in kids and adolescents with Hodgkin lymphoma. twenty. Herling M, Rassidakis GZ, Vassilakopoulos TP, et al.: Impact of LMP-1 expression on clinical end result in age-outlined subgroups of people with classical Hodgkin lymphoma. eighteen. Jarrett RF, Stark GL, White J, et al.: Impact of tumor Epstein-Barr virus standing on presenting capabilities and final result in age-defined subgroups of sufferers with classic Hodgkin lymphoma: a inhabitants-based research. forty one. Kahn JM, Kelly KM, Pei Q, et al.: Survival by Race and Ethnicity in Pediatric and Adolescent Patients With Hodgkin Lymphoma: A Children’s Oncology Group Study. 29. Steidl C, Connors JM, Gascoyne RD: Molecular pathogenesis of Hodgkin’s lymphoma: escalating proof of the value of the microenvironment.
40. Metzger ML, Castellino SM, Hudson MM, et al.: Effect of race on the final result of pediatric sufferers with Hodgkin’s lymphoma. 22. Hjalgrim H, Askling J, Rostgaard K, et al.: Characteristics of Hodgkin’s lymphoma soon after infectious mononucleosis. 5. Grufferman S, Delzell E: Epidemiology of Hodgkin’s ailment. 30. Nachman JB, Sposto R, Herzog P, et al.: Randomized comparison of very low-dose concerned-industry radiotherapy and no radiotherapy for children with Hodgkin’s sickness who obtain a full response to chemotherapy. 38. Landman-Parker J, Pacquement H, Leblanc T, et al.: Localized childhood Hodgkin’s disease: response-tailored chemotherapy with etoposide, bleomycin, vinblastine, and prednisone in advance of minimal-dose radiation therapy-final results of the French Society of Pediatric Oncology Study MDH90. 9. Crump C, Sundquist K, Sieh W, et al.: Perinatal and loved ones possibility aspects for Hodgkin lymphoma in childhood by younger adulthood. 27. Knight JS, Tsodikov A, Cibrik DM, et al.: Lymphoma immediately after stable organ transplantation: possibility, response to therapy, and survival at a transplantation heart. Lavasani M, Robinson AR, Lu A, Song M, Feduska JM, Ahani B, Tilstra JS, Feldman CH, Robbins PD, Niedernhofer LJ, Huard J (January 2012). «Muscle-derived stem/progenitor cell dysfunction boundaries healthspan and lifespan in a murine progeria model». The rapidity of reaction to preliminary cycles of chemotherapy also appears to be prognostically important.
